---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023014"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T21:18:48.915873+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics stockholders approve 3M share increase to 2016 Incentive Plan

## Summary
- Stockholders elected all four director nominees: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh.
- Ratified Deloitte & Touche LLP as independent auditor for fiscal year 2023.
- Advisory vote approved executive compensation with 18.9M for and 0.6M against.
- Amended 2016 Omnibus Plan approved to increase shares reserved by 3M (10.8M for, 8.7M against).
- Plan amendment adds 3M shares, representing ~10% dilution relative to 29.7M shares outstanding.

## SEC filing metadata
- accession: 0000950170-23-023014
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/0000950170-23-023014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/flgt-20230518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023014
- JSON: https://secwatch.observer/filing/0000950170-23-023014.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023014.txt

## Key facts
- Shareholder Votes
  Fulgent Genetics, Inc. shareholders approved Election of directors at the 2023-05-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2024 Annual Meeting and until his or her successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/0000950170-23-023014-index.htm
- Shareholder Votes
  Fulgent Genetics, Inc. shareholders approved Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares at the 2023-05-18 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal 4 Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/0000950170-23-023014-index.htm
- Shareholder Votes
  Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of our named executive officers at the 2023-05-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal 3 Approval, on a non-binding advisory basis, the compensation of our named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/0000950170-23-023014-index.htm
- Shareholder Votes
  Fulgent Genetics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal 2 Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023023014/0000950170-23-023014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.